Drug Profile
Research programme: cancer and CNS disorder therapeutics - Angiochem
Alternative Names: ANG 3201; ANG-1009; ANG-1011; ANG-2004; ANG-2008; ANG-3101; ANG-3202; Angiopep-antibody-drug conjugate - AngiochemLatest Information Update: 28 Oct 2020
Price :
$50
*
At a glance
- Originator AngioChem
- Class Drug conjugates; Monoclonal antibodies; Peptides; Small molecules
- Mechanism of Action Brain derived neurotrophic factor modulators; DNA intercalators; ERBB 2 receptor antagonists; Glucagon like peptide 1 receptor agonists; Immunomodulators; Leptin receptor modulators; Neurotensin receptor modulators; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Brain metastases; Cancer; Pain
- Discontinued Brain cancer; Diabetes mellitus; Neurological disorders; Obesity; Parkinson's disease
Most Recent Events
- 28 Oct 2020 No recent reports of development identified for research development in Cancer in Canada (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Brain metastases in Canada (IV, Injection)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Pain in Canada